UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
VANCOUVER, BC, June 13, 2025 /CNW/ – UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation.
The two newly funded platforms are:
International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for patients.Total Grant Awarded: $1,866,750
The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain disorders.Total Grant Awarded: $4,845,000
'This platform represents a critical step toward advancing spinal cord injury research globally,' said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. 'By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients.'
'With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience,' said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. 'By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments.'
These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders.
'The UBC neuroscience community is grateful for Brain Canada's continued support,' said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. 'These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan.'
Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: 'By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives.'
These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month.
Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape.
'Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries,' said the Honourable Marjorie Michel, Minister of Health. 'Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 days ago
- Malaysian Reserve
UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
VANCOUVER, BC, June 13, 2025 /CNW/ – UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation. The two newly funded platforms are: International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for Grant Awarded: $1,866,750 The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain Grant Awarded: $4,845,000 'This platform represents a critical step toward advancing spinal cord injury research globally,' said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. 'By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients.' 'With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience,' said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. 'By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments.' These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders. 'The UBC neuroscience community is grateful for Brain Canada's continued support,' said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. 'These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan.' Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: 'By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives.' These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. 'Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries,' said the Honourable Marjorie Michel, Minister of Health. 'Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes.'
Malaysian Reserve
06-06-2025
- Malaysian Reserve
Changing Systems, One Story at a Time: National Summit Reimagines Obesity Care Through Community, Connection, and Compassion
TORONTO, June 6, 2025 /CNW/ – Sunday, June 8, 2025 — National advocacy organization Obesity Matters will host the Your Health Matters Summit 2025 at the historic Old Mill Toronto, with virtual access available across Canada. This one-day, community-powered event is creating space for real stories, honest conversations, and stigma-free care — putting people, not just conditions, at the center of health and wellness. With the theme 'Inspire Change. Build Connection. Advance Wellness.', the summit brings together healthcare professionals, lived experience advocates, and community leaders to explore how we can shift the narrative around health — from judgment to empathy, and from isolation to meaningful support. 'Obesity isn't a character flaw — it's a chronic condition that deserves empathy, science, and dignity,' says Priti Chawla, Executive Director of Obesity Matters.'This summit is about rewriting the narrative — one story, one connection, one person at a time.' Program highlights include: Dr. Sean Wharton and Dr. Gillian Mandich on self-compassion and emotional resilience Dr. Megha Poddar on hormone health across life stages Dr. Peter Selby facilitating a storytelling session with patient advocates Dr. David Macklin on Resilience… The Secret Skill to Success A featured session on Body Image, Stigma, and the Age of Anti-Obesity Medication will be led by Dr. Sandy Van and Sandra Elia, Chair of Obesity Matters. 'We can't let outdated ideals or social media define what health looks like,' says Dr. Sandy Van.'In the era of obesity medication, the pressure to meet unrealistic appearance goals can take a real psychological toll. Effective care must be rooted in evidence, with compassion for both the body and the mind.' 'For too long, people have carried the weight of shame when what they needed was care. At this summit, we are rewriting that story — one rooted in love, science, and the belief that every person deserves access to evidence-based treatment.' — Sandra Elia, Chair, Obesity Matters For full program details, visit:
Malaysian Reserve
06-06-2025
- Malaysian Reserve
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ – GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. 'As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges,' said Michelle Horn, Country Medical Director, GSK Canada. 'Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred.' Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. 'As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries,' said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. 'PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally.' Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. 'Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare,' added Michelle Horn, Country Medical Director, GSK Canada. 'We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health.' Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of PharmacyThe School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.
